Premium
Cartilage Oligomeric Matrix Protein Level in Rheumatic Diseases
Author(s) -
MOROZZI GABRIELLA,
FABBRONI MARTA,
BELLISAI FRANCESCA,
PUCCI GABRIELLA,
GALEAZZI MAURO
Publication year - 2007
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1422.041
Subject(s) - cartilage oligomeric matrix protein , medicine , rheumatoid arthritis , cartilage , arthritis , inflammation , osteoarthritis , synovial fluid , tumor necrosis factor alpha , immunology , pathology , anatomy , alternative medicine
: Cartilage oligomeric matrix protein (COMP) is a tissue‐specific noncollagenous protein that was first detected in the serum and the synovial fluid of patients suffering from rheumatic disorders, such as rheumatoid arthritis, reactive arthritis, juvenile chronic arthritis, and osteoarthritis. In this review, the authors consider serum COMP levels in different diseases and discuss their study of patients with rheumatoid arthritis treated with anti‐TNF‐α, to evaluate whether COMP is able to predict a rapid and sustained clinical response to these drugs. They observe that patients with high COMP levels have a lower ACR 70 response independently of the state of systemic inflammation, and conclude that COMP seems to have a pathogenetic role that is independent of the mechanisms regulating inflammatory processes .